Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.62 |
| ▸ | HPGD | P15428 | 6/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.50 |
| ▸ | GAA | P10253 | 3/20 | 0.50 |
| ▸ | NPC1 | O15118 | 3/20 | 0.50 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.49 |
| ▸ | POLB | P06746 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 3/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.48 |
| ▸ | MITF | O75030 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | RECQL | P46063 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4422568 | 1.00 | MAPT (0.62) | MAPTHPGDKDM4EGAANPC1 | |
| SCHEMBL4425026 | 0.83 | HDAC4 (0.65) | MAPTHPGDKDM4EGAANPC1 | |
| SCHEMBL4425023 | 0.83 | HDAC4 (0.65) | MAPTHPGDKDM4EGAANPC1 | |
| SCHEMBL4945600 | 0.75 | ALDH1A1 (0.67) | MAPTHPGDKDM4EGAANPC1 | |
| SCHEMBL17537884 | 0.75 | CA12 (0.53) | MAPTHPGDKDM4EGAAALDH1A1 | |
| SCHEMBL624327 | 0.74 | ALDH1A1 (0.60) | MAPTHPGDKDM4EGAANPC1 | |
| SCHEMBL6415702 | 0.74 | MEN1 (0.59) | MAPTHPGDKDM4EGAANPC1 | |
| SCHEMBL6415697 | 0.74 | MEN1 (0.59) | MAPTHPGDKDM4EGAANPC1 | |
| SCHEMBL933091 | 0.73 | CYP1A2 (0.67) | MAPTHPGDNPC1RAB9AKMT2A | |
| SCHEMBL2500242 | 0.73 | CYP1A2 (0.67) | MAPTHPGDNPC1RAB9AKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1682538-A4 | BIARYL LINKED HYDROXAMATES: PREPARATION AND PHARMACEUTICAL APPLICATIONS | S BIO PTE LTD (SG) | 2009-05-27 | — | — | EP | disclosed |
| US-20070167499-A1 | Biaryl linked hydroxamates: preparation and pharmaceutical applications | A*BIO PTE LTD. (SG) | 2007-07-19 | — | — | US | disclosed |
| US-20070167499-A1 | Biaryl linked hydroxamates: preparation and pharmaceutical applications | A*BIO PTE LTD. (SG) | 2007-07-19 | — | — | US | disclosed |
| US-20070167499-A1 | Biaryl linked hydroxamates: preparation and pharmaceutical applications | A*BIO PTE LTD. (SG) | 2007-07-19 | — | — | US | disclosed |
| EP-1682538-A1 | BIARYL LINKED HYDROXAMATES: PREPARATION AND PHARMACEUTICAL APPLICATIONS | S*Bio Pte Ltd (SG) | 2006-07-26 | — | — | EP | disclosed |
| WO-2005040161-A1 | BIARYL LINKED HYDROXAMATES: PREPARATION AND PHARMACEUTICAL APPLICATIONS | S*BIO PTE LTD (SG) | 2005-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070167499-A1 | Biaryl linked hydroxamates: preparation and pharmaceutical applications | HDAC1, HDAC11, HDAC2 | MAPT 3965/4885HPGD 237/4885KDM4E 454/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.